Dean J. Kereiakes et al. JACC 2017;70:

Slides:

Advertisements

Similar presentations

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

Advertisements

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Beta-Blockers and Outcome in Heart Failure and Atrial.

Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention.

Date of download: 9/19/2016 From: The Implications of Regional Variations in Medicare Spending. Part 2: Health Outcomes and Satisfaction with Care Ann.

Is the Debate Over? Routine Thrombus Aspiration in STEMI (From TAPAS to INFUSE-AMI to TASTE to TOTAL) Stefan James Professor of Cardiology Uppsala Clinical.

Discontinuation of medication after nonfatal event: MI

Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT.

Prakash Harikrishnan et al. JACEP 2015;1:

Clyde W. Yancy et al. JACC 2017;70:

Robert W. Yeh et al. JACC 2017;70:

Robert W. Yeh et al. JACC 2017;70:

Robert W. Yeh et al. JACC 2017;70:

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Kenshi Hayashi et al. JACEP 2016;2:

Ashish Shukla et al. JACEP 2015;1:41-51

Johannes Steiner et al. JACC 2017;70:

Belinda Gray et al. JCHF 2013;1:

Sébastien P.J. Krul et al. JACEP 2015;1:

Juan J. Russo et al. JACC 2019;73:

Prakash Harikrishnan et al. JACEP 2015;1:

Wayne L. Miller et al. JCHF 2013;1:

Mohit K. Turagam et al. JACEP 2017;3:

David J.A. Jenkins et al. JACC 2018;71:

Jonathan Afilalo et al. JACC 2017;j.jacc

John A. Bittl et al. JACC 2016;68:

Khurram Nasir et al. JACC 2015;66:

Prakash Harikrishnan et al. JACEP 2015;1:

Rachel Bastiaenen et al. JACEP 2016;2:

On Statin Treatment to Prevent Sepsis in Dialysis Patients

Nicolaj C. Hansson et al. JACC 2016;68:

APD Restitution and Ventricular Arrhythmia Inducibility (A to D) Examples of dynamic APD restitution curves at remote (A and C) and peri-infarcted (B and.

Emilce Trucco et al. JACEP 2018;j.jacep

Marwan Badri et al. JACEP 2015;1:

Vittorio Calzolari et al. JACEP 2017;3:

Kenshi Hayashi et al. JACEP 2016;2:

Toshiaki Toyota et al. JCIN 2017;10:27-37

Vittorio Calzolari et al. JACEP 2017;3:

Peter E. Carson et al. JCHF 2015;3:

Maria R. Costanzo et al. JCHF 2016;4:

Mintu P. Turakhia et al. JACEP 2016;2:

Emilce Trucco et al. JACEP 2018;j.jacep

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Dennis G. Moledina, MD, Mark A. Perazella, MD

Björn Redfors et al. JACEP 2017;j.jacep

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

John Rickard et al. JCHF 2013;1:

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Sebastiano Sciarretta et al. JACC 2018;71:

Giuseppe Gargiulo et al. JACC 2018;71:

Jeffrey L. Anderson et al. JACC 2007;50:e1-e157

Svend A. Mortensen et al. JCHF 2014;2:

Ronan Abgral et al. JIMG 2017;10:

Stavros V. Konstantinides et al. JACC 2017;69:

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

Davide Capodanno et al. JCIN 2009;2:

Ingrid Kindermann et al. JACC 2012;59:

Jeffrey J. Teuteberg et al. JCHF 2015;3:

Saadia Sherazi et al. JACEP 2015;1:74-80

Pamela E. Scott et al. JACC 2018;71:

Steven R. Steinhubl, and Eric J. Topol JACC 2015;66:

Christian Madelaire et al. JCHF 2018;6:

Constantijn Franssen et al. JCHF 2016;4:

Jeffrey Senfield et al. JACEP 2017;3:

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Maxime Berthelot-Richer et al. JIMG 2016;9:

Orly Vardeny et al. JCHF 2016;4:

Gianluigi Savarese et al. JCHF 2016;4:

Presentation transcript:

Dean J. Kereiakes et al. JACC 2017;70:2852-2862 Subgroup Analyses for the 3-Year Rates of TLF in Patients Assigned to BVS Versus EES Interaction testing demonstrated that outcomes by randomized device were consistent across 9 pre-specified subgroups. ACC = American College of Cardiology; AHA = American Heart Association; RR = relative risk; MI = myocardial infarction; TLF = target lesion failure; other abbreviations as in Figures 1 and 2. Dean J. Kereiakes et al. JACC 2017;70:2852-2862 2017 American College of Cardiology Foundation